Abstract
Positron emission tomography/magnetic resonance (PET/MR) imaging systems enable a multiparametric imaging approach in neuro-oncology by combining anatomical and functional information from standard and advanced MR sequences with the metabolic and molecular data provided by PET imaging in a single session. Although conventional MR imaging is considered the standard imaging modality in neuro-oncology, it has diagnostic limitations in the evaluation of brain tumors. The combination of PET and MR in PET/MR imaging has the potential to further enhance diagnostic accuracy in neuro-oncological imaging. The most common primary malignant central nervous system pathologies are gliomas in both children and adults. In neuro-oncology, PET/MR imaging, particularly with F-18 fluorodeoxyglucose and amino acid-labeled PET radiopharmaceuticals, can be used for primary diagnosis, tumor grading and biopsy site planning, assessing tumor extent, and differentiating treatment-related changes from recurrent disease. Studies have generally shown that the combined use of parameters obtained from PET and MR enhances diagnostic performance in these indications. The aim of this review is to explain the advantages and limitations of PET/MR imaging in neuro-oncology, particularly in gliomas, as well as the fundamentals of PET and MR components, and the clinical role of hybrid PET/MR.
Keywords: Positron emission tomography/magnetic resonance imaging, hybrid imaging, glioma, meningioma, brain tumors
References
Ostrom QT, Francis SS, Barnholtz-Sloan JS. Epidemiology of brain and other CNS tumors. Curr Neurol Neurosci Rep. 2021;21:68.
Schaff LR, Mellinghoff IK. Glioblastoma and other primary brain malignancies in adults: a review. JAMA. 2023;329:574-587.
Louis DN, Perry A, Wesseling P, et al. The 2021 WHO classification of tumors of the central nervous system: a summary. Neuro Oncol. 2021;23:1231-1251.
Torp SH, Solheim O, Skjulsvik AJ. The WHO 2021 Classification of central nervous system tumours: a practical update on what neurosurgeons need to know-a minireview. Acta Neurochir (Wien). 2022;164:2453-2464.
Overcast WB, Davis KM, Ho CY, et al. Advanced imaging techniques for neuro-oncologic tumor diagnosis, with an emphasis on PET-MRI imaging of malignant brain tumors. Curr Oncol Rep. 2021;23:34.
Marner L, Henriksen OM, Lundemann M, Larsen VA, Law I. Clinical PET/MRI in neurooncology: opportunities and challenges from a single-institution perspective. Clin Transl Imaging. 2017;5:135-149.
Miller-Thomas MM, Benzinger TL. Neurologic applications of PET/MR imaging. Magn Reson Imaging Clin N Am. 2017;25:297-313.
Henriksen OM, Marner L, Law I. Clinical PET/MR imaging in dementia and neuro-oncology. PET Clin. 2016;11:441-452.
Catana C, Benner T, van der Kouwe A, et al. MRI-assisted PET motion correction for neurologic studies in an integrated MR-PET scanner. J Nucl Med. 2011;52:154-161.
Delso G, Wiesinger F, Sacolick LI, et al. Clinical evaluation of zero-echo-time MR imaging for the segmentation of the skull. J Nucl Med. 2015;56:417-422.
Navalpakkam BK, Braun H, Kuwert T, Quick HH. Magnetic resonance-based attenuation correction for PET/MR hybrid imaging using continuous valued attenuation maps. Invest Radiol. 2013;48:323-332.
Law I, Albert NL, Arbizu J, et al. Joint EANM/EANO/RANO practice guidelines/SNMMI procedure standards for imaging of gliomas using PET with radiolabelled amino acids and [18F]FDG: version 1.0. Eur J Nucl Med Mol Imaging. 2019;46:540-557.
Veit-Haibach P, Ahlström H, Boellaard R, et al. International EANM-SNMMI-ISMRM consensus recommendation for PET/MRI in oncology. Eur J Nucl Med Mol Imaging. 2023;50:3513-3537.
Schwenzer NF, Stegger L, Bisdas S, et al. Simultaneous PET/MR imaging in a human brain PET/MR system in 50 patients--current state of image quality. Eur J Radiol. 2012;81:3472-3478.
Davide S, Consuelo V, Antonio M, et al. Spatial relationships of MR imaging and positron emission tomography with phenotype, genotype and tumor stem cell generation in glioblastoma multiforme. In: Lee Roy M, editor. Tumors of the central nervous system. Rijeka: IntechOpen; 2014. p. Ch. 3.
Guedj E, Varrone A, Boellaard R, et al. EANM procedure guidelines for brain PET imaging using [18F]FDG, version 3. Eur J Nucl Med Mol Imaging. 2022;49:632-651.
Albert NL, Weller M, Suchorska B, et al. Response Assessment in Neuro-Oncology working group and European Association for Neuro-Oncology recommendations for the clinical use of PET imaging in gliomas. Neuro Oncol. 2016;18:1199-1208.
Kosaka N, Tsuchida T, Uematsu H, Kimura H, Okazawa H, Itoh H. 18F-FDG PET of common enhancing malignant brain tumors. AJR Am J Roentgenol. 2008;190:W365-W369.
Omuro AM, Leite CC, Mokhtari K, Delattre JY. Pitfalls in the diagnosis of brain tumours. Lancet Neurol. 2006;5:937-948.
Delbeke D, Meyerowitz C, Lapidus RL, et al. Optimal cutoff levels of F-18 fluorodeoxyglucose uptake in the differentiation of low-grade from high-grade brain tumors with PET. Radiology. 1995;195:47-52.
Fink JR, Muzi M, Peck M, Krohn KA. Multimodality brain tumor imaging: MR imaging, PET, and PET/MR imaging. J Nucl Med. 2015;56:1554-1561.
Manabe O, Hattori N, Yamaguchi S, et al. Oligodendroglial component complicates the prediction of tumour grading with metabolic imaging. Eur J Nucl Med Mol Imaging. 2015;42:896-904.
Zhang G, Li J, Hui X. Use of 18F-FDG-PET/CT in differential diagnosis of primary central nervous system lymphoma and high-grade gliomas: A meta-analysis. Front Neurol. 2022;13:935459.
Horowitz T, Tabouret E, Graillon T, et al. Contribution of nuclear medicine to the diagnosis and management of primary brain tumours. Rev Neurol (Paris). 2023;179:394-404.
Rozenblum L, Houillier C, Soussain C, et al. Role of positron emission tomography in primary central nervous system lymphoma. Cancers (Basel). 2022;14:4071.
Spence AM, Mankoff DA, Muzi M. The role of PET in the management of brain tumors. Appl Radiol. 2007;36:8.
Spence AM, Muzi M, Graham MM, et al. 2-[(18)F]Fluoro-2-deoxyglucose and glucose uptake in malignant gliomas before and after radiotherapy: correlation with outcome. Clin Cancer Res. 2002;8:971-979.
Charnley N, West CM, Barnett CM, et al. Early change in glucose metabolic rate measured using FDG-PET in patients with high-grade glioma predicts response to temozolomide but not temozolomide plus radiotherapy. Int J Radiat Oncol Biol Phys. 2006;66:331-338.
Colavolpe C, Metellus P, Mancini J, et al. Independent prognostic value of pre-treatment 18-FDG-PET in high-grade gliomas. J Neurooncol. 2012;107:527-535.
Omuro A, Beal K, Gutin P, et al. Phase II study of bevacizumab, temozolomide, and hypofractionated stereotactic radiotherapy for newly diagnosed glioblastoma. Clin Cancer Res. 2014;20:5023-5031.
Galldiks N, Lohmann P, Fink GR, Langen K-J. Amino acid PET in neurooncology. J Nucl Med. 2023;64:693.
Dunet V, Pomoni A, Hottinger A, Nicod-Lalonde M, Prior JO. Performance of 18F-FET versus 18F-FDG-PET for the diagnosis and grading of brain tumors: systematic review and meta-analysis. Neuro Oncol. 2016;18:426-434.
Jansen NL, Graute V, Armbruster L, et al. MRI-suspected low-grade glioma: is there a need to perform dynamic FET PET? Eur J Nucl Med Mol Imaging. 2012;39:1021-1029.
Rapp M, Heinzel A, Galldiks N, et al. Diagnostic performance of 18F-FET PET in newly diagnosed cerebral lesions suggestive of glioma. J Nucl Med. 2013;54:229-235.
Jansen NL, Schwartz C, Graute V, et al. Prediction of oligodendroglial histology and LOH 1p/19q using dynamic [(18)F]FET-PET imaging in intracranial WHO grade II and III gliomas. Neuro Oncol. 2012;14:1473-1480.
Pöpperl G, Kreth FW, Mehrkens JH, et al. FET PET for the evaluation of untreated gliomas: correlation of FET uptake and uptake kinetics with tumour grading. Eur J Nucl Med Mol Imaging. 2007;34:1933-1942.
Kracht LW, Miletic H, Busch S, et al. Delineation of brain tumor extent with [11C]L-methionine positron emission tomography: local comparison with stereotactic histopathology. Clin Cancer Res. 2004;10:7163-7170.
Pafundi DH, Laack NN, Youland RS, et al. Biopsy validation of 18F-DOPA PET and biodistribution in gliomas for neurosurgical planning and radiotherapy target delineation: results of a prospective pilot study. Neuro Oncol. 2013;15:1058-1067.
Ledezma CJ, Chen W, Sai V, et al. 18F-FDOPA PET/MRI fusion in patients with primary/recurrent gliomas: initial experience. Eur J Radiol. 2009;71:242-28.
Song S, Wang L, Yang H, et al. Static (18)F-FET PET and DSC-PWI based on hybrid PET/MR for the prediction of gliomas defined by IDH and 1p/19q status. Eur Radiol. 2021;31:4087-4096.
Galldiks N, Langen K-J, Holy R, et al. Assessment of treatment response in patients with glioblastoma using O-(2-18F-fluoroethyl)-L-tyrosine PET in comparison to MRI. J Nucl Med. 2012;53:1048-1057.
Galldiks N, Kracht LW, Burghaus L, et al. Use of 11C-methionine PET to monitor the effects of temozolomide chemotherapy in malignant gliomas. Eur J Nucl Med Mol Imaging. 2006;33:516-524.
Almansory KO, Fraioli F. Combined PET/MRI in brain glioma imaging. Br J Hosp Med (Lond). 2019;80:380-386.
de Zwart PL, van Dijken BRJ, Holtman GA, et al. diagnostic accuracy of PET tracers for the differentiation of tumor progression from treatment-related changes in high-grade glioma: a systematic review and metaanalysis. J Nucl Med. 2020;61:498-504.
Cui M, Zorrilla-Veloz RI, Hu J, Guan B, Ma X. Diagnostic accuracy of pet for differentiating true glioma progression from post treatment-related changes: a systematic review and meta-analysis. Front Neurol. 2021;12:671867.
Tsiouris S, Bougias C, Fotopoulos A. Principles and current trends in the correlative evaluation of glioma with advanced MRI techniques and PET. Hell J Nucl Med. 2019;22:206-219.
Mišir Krpan A, Hodolič M, Golubić AT, et al. 18F-FET and 18F-choline PET-CT in patients with MRI-suspected low-grade gliomas: a pilot study. Croat Med J. 2021;62:310-317.
Verburg N, Koopman T, Yaqub M, et al. Direct comparison of [11C] choline and [18F] FET PET to detect glioma infiltration: a diagnostic accuracy study in eight patients. EJNMMI Res. 2019;9:57.
Cher LM, Murone C, Lawrentschuk N, et al. Correlation of hypoxic cell fraction and angiogenesis with glucose metabolic rate in gliomas using 18F-fluoromisonidazole, 18F-FDG PET, and immunohistochemical studies. J Nucl Med. 2006;47:410-418.
Muzi M, Spence AM, O'Sullivan F, et al. Kinetic analysis of 3'-deoxy-3'-18F-fluorothymidine in patients with gliomas. J Nucl Med. 2006;47:1612-1621.
Muoio B, Albano D, Dondi F, et al. Diagnostic accuracy of PET/CT or PET/MRI using PSMA-targeting radiopharmaceuticals in high-grade gliomas: a systematic review and a bivariate meta-analysis. Diagnostics (Basel). 2022;12:1665.
Filippi L, Palumbo I, Bagni O, Schillaci O, Aristei C, Palumbo B. Somatostatin receptor targeted PET-imaging for diagnosis, radiotherapy planning and theranostics of meningiomas: a systematic review of the literature. Diagnostics (Basel). 2022;12:1666.
Hilario A, Ramos A, Perez-Nuñez A, et al. The added value of apparent diffusion coefficient to cerebral blood volume in the preoperative grading of diffuse gliomas. AJNR Am J Neuroradiol. 2012;33:701-707.
Guo AC, Cummings TJ, Dash RC, Provenzale JM. Lymphomas and high-grade astrocytomas: comparison of water diffusibility and histologic characteristics. Radiology. 2002;224:177-183.
Ferda J, Ferdová E, Hes O, Mraček J, Kreuzberg B, Baxa J. PET/MRI: Multiparametric imaging of brain tumors. Eur J Radiol. 2017;94:A14-A25.
Montagne A, Toga AW, Zlokovic BV. Blood-brain barrier permeability and gadolinium: benefits and potential pitfalls in research. JAMA Neurol. 2016;73:13-14.
Wen PY, Macdonald DR, Reardon DA, et al. Updated response assessment criteria for high-grade gliomas: response assessment in neuro-oncology working group. J Clin Oncol. 2010;28:1963-1972.
Patel P, Baradaran H, Delgado D, et al. MR perfusion-weighted imaging in the evaluation of high-grade gliomas after treatment: a systematic review and meta-analysis. Neuro Oncol. 2017;19:118-127.
Jain R. Measurements of tumor vascular leakiness using DCE in brain tumors: clinical applications. NMR Biomed. 2013;26:1042-1049.
Law M, Yang S, Wang H, et al. Glioma grading: sensitivity, specificity, and predictive values of perfusion MR imaging and proton MR spectroscopic imaging compared with conventional MR imaging. AJNR Am J Neuroradiol. 2003;24:1989-1998.
Schmainda KM, Zhang Z, Prah M, et al. Dynamic susceptibility contrast MRI measures of relative cerebral blood volume as a prognostic marker for overall survival in recurrent glioblastoma: results from the ACRIN 6677/RTOG 0625 multicenter trial. Neuro Oncol. 2015;17:1148-1156.
Wang Q, Zhang H, Zhang J, et al. The diagnostic performance of magnetic resonance spectroscopy in differentiating high-from low-grade gliomas: A systematic review and meta-analysis. Eur Radiol. 2016;26:2670-2684.
Zhang H, Ma L, Wang Q, Zheng X, Wu C, Xu BN. Role of magnetic resonance spectroscopy for the differentiation of recurrent glioma from radiation necrosis: a systematic review and meta-analysis. Eur J Radiol. 2014;83:2181-2189.
Jena A, Taneja S, Jha A, et al. Multiparametric evaluation in differentiating glioma recurrence from treatment-induced necrosis using simultaneous (18)F-FDG-PET/MRI: a single-institution retrospective study. AJNR Am J Neuroradiol. 2017;38:899-907.
Mauler J, Maudsley AA, Langen KJ, et al. Spatial relationship of glioma volume derived from (18)F-FET PET and volumetric MR spectroscopy imaging: a hybrid PET/MRI study. J Nucl Med. 2018;59:603-609.
Henriksen OM, Larsen VA, Muhic A, et al. Simultaneous evaluation of brain tumour metabolism, structure and blood volume using [(18)F]-fluoroethyltyrosine (FET) PET/MRI: feasibility, agreement and initial experience. Eur J Nucl Med Mol Imaging. 2016;43:103-112.
Nabors LB, Portnow J, Ahluwalia M, et al. Central nervous system cancers, version 1.2024, NCCN clinical practice guidelines in oncology. J Natl Compr Canc Netw. 2024;18:1537-1570.
Şeker K, Çeltikçi E, Aydos U, et al. Quantitative parameters from 18F-FDG PET/MRI reveal intratumoral heterogeneity in primer brain tumors confirmed by pathology. Eur J Nucl Med Mol Imaging. 2021;48.
Zhang S, Wang J, Wang K, et al. Differentiation of high-grade glioma and primary central nervous system lymphoma: Multiparametric imaging of the enhancing tumor and peritumoral regions based on hybrid 18F-FDG PET/MRI. Eur J Radiol. 2022;150:110235.
Brendle C, Maier C, Bender B, et al. Impact of 18F-FET PET/MRI on clinical management of brain tumor patients. J Nucl Med. 2022;63:522-527.
Mauler J, Lohmann P, Maudsley AA, et al. Diagnostic accuracy of MR spectroscopic imaging and 18F-FET PET for identifying glioma: a biopsy-controlled hybrid PET/MRI study. J Nucl Med. 2024;65:16-21.
Verger A, Filss CP, Lohmann P, et al. Comparison of 18F-FET PET and perfusion-weighted MRI for glioma grading: a hybrid PET/MR study. Eur J Nucl Med Mol Imaging. 2017;44:2257-2265.
Pyka T, Krzyzanowska I, Rominger A, et al. Multiparametric characterization of intracranial gliomas using dynamic [18F]FET-PET and magnetic resonance spectroscopy. Diagnostics (Basel). 2022;12:2331.
Harat M, Rakowska J, Harat M, et al. Combining amino acid PET and MRI imaging increases accuracy to define malignant areas in adult glioma. Nat Commun. 2023;14:4572.
Göttler J, Lukas M, Kluge A, et al. Intra-lesional spatial correlation of static and dynamic FET-PET parameters with MRI-based cerebral blood volume in patients with untreated glioma. Eur J Nucl Med Mol Imaging. 2017;44:392-397.
Filss CP, Galldiks N, Stoffels G, et al. Comparison of 18F-FET PET and perfusion-weighted MR imaging: a PET/MR imaging hybrid study in patients with brain tumors. J Nucl Med. 2014;55:540-545.
Ort J, Hamou HA, Kernbach JM, et al. 18F-FET-PET-guided gross total resection improves overall survival in patients with WHO grade III/IV glioma: moving towards a multimodal imaging-guided resection. J Neurooncol. 2021;155:71-80.
Seidlitz A, Beuthien-Baumann B, Löck S, et al. Final results of the prospective biomarker trial PETra: [11C]-MET-accumulation in postoperative PET/MRI predicts outcome after radiochemotherapy in glioblastoma. Clin Cancer Res. 2021;27:1351-1360.
Pyatigorskaya N, Sgard B, Bertaux M, Yahia-Cherif L, Kas A. Can FDG-PET/MR help to overcome limitations of sequential MRI and PET-FDG for differential diagnosis between recurrence/progression and radionecrosis of high-grade gliomas? J Neuroradiol. 2021;48:189-194.
Peer S, Gopinath R, Saini J, Kumar P, Srinivas D, Nagaraj C. Evaluation of the diagnostic performance of f18-fluorodeoxyglucose-positron emission tomography, dynamic susceptibility contrast perfusion, and apparent diffusion coefficient in differentiation between recurrence of a high-grade glioma and radiation necrosis. Indian J Nucl Med. 2023;38:115-124.
Hojjati M, Badve C, Garg V, et al. Role of FDG-PET/MRI, FDG-PET/CT, and dynamic susceptibility contrast perfusion MRI in differentiating radiation necrosis from tumor recurrence in glioblastomas. J Neuroimaging. 2018;28:118-125.
Deuschl C, Kirchner J, Poeppel TD, et al. (11)C-MET PET/MRI for detection of recurrent glioma. Eur J Nucl Med Mol Imaging. 2018;45:593-601.
Jabeen S, Arbind A, Kumar D, et al. Combined amino acid PET-MRI for identifying recurrence in post-treatment gliomas: together we grow. Eur J Hybrid Imaging. 2021;5:15.
Smith NJ, Deaton TK, Territo W, et al. Hybrid (18)F-fluoroethyltyrosine PET and MRI with perfusion to distinguish disease progression from treatment-related change in malignant brain tumors: the quest to beat the toughest cases. J Nucl Med. 2023;64:1087-1092.
Pyka T, Hiob D, Preibisch C, et al. Diagnosis of glioma recurrence using multiparametric dynamic 18F-fluoroethyl-tyrosine PET-MRI. Eur J Radiol. 2018;103:32-37.
Soni N, Ora M, Jena A, et al. Amino acid tracer PET MRI in glioma management: what a neuroradiologist needs to know. AJNR Am J Neuroradiol. 2023;44:236-246.
Prather KY, O'Neal CM, Westrup AM, et al. A systematic review of amino acid PET in assessing treatment response to temozolomide in glioma. Neurooncol Adv. 2022;4:vdac008.
Deuschl C, Moenninghoff C, Goericke S, et al. Response assessment of bevacizumab therapy in GBM with integrated 11C-MET-PET/MRI: a feasibility study. Eur J Nucl Med Mol Imaging. 2017;44:1285-1295.
Lombardi G, Spimpolo A, Berti S, et al. PET/MR in recurrent glioblastoma patients treated with regorafenib: [(18)F]FET and DWI-ADC for response assessment and survival prediction. Br J Radiol. 2022;95:20211018.
Gauvain K, Ponisio MR, Barone A, et al. (18)F-FDOPA PET/MRI for monitoring early response to bevacizumab in children with recurrent brain tumors. Neurooncol Pract. 2018;5:28-36.
Milosevic A, Styczen H, Grueneisen J, et al. Evaluation of [(68)Ga]-DOTATOC PET/MRI in patients with meningioma of the subcranial and intraorbital space. J Nucl Med. 2023;64:1185-1190.
Milosevic A, Styczen H, Haubold J, et al. Correlation of the apparent diffusion coefficient with the standardized uptake value in meningioma of the skull plane using [68]Ga-DOTATOC PET/MRI. Nucl Med Commun. 2023;44:1106-1113.
Mahase SS, Roth O'Brien DA, No D, et al. [(68)Ga]-DOTATATE PET/MRI as an adjunct imaging modality for radiation treatment planning of meningiomas. Neurooncol Adv. 2021;3:vdab012.
